Navigation Links
Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
Date:4/11/2013

(PRWEB) April 11, 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will be exhibiting and presenting at the 2013 Global Formulation and Drug Delivery Summit in Amsterdam, The Netherlands.

Tony Pigeon, one of Patheon’s scientific experts will be present at the show. Tony is the Senior Manager, Global Science and Technology at Patheon. During his more than 30 year career, he has acquired a considerable degree of experience working with big pharmaceuticals and small biotechs. His diverse experience in the field of drug product development ranges from pre-formulation to process validation for a wide range of dosage forms, including tablets, capsules, semi-solids, sterile solution and suspension products, oral solution and suspension products and aerosols.

Other Patheon representatives will also be available to meet at the Global Formulation and Drug Delivery summit exhibit hall from April 23-24, 2013, showcasing several of Patheon’s key service offerings. Learn more by visiting Patheon’s booth during the conference. To schedule a meeting in advance send an email to events(at)patheon(dot)com.

For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a pro
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
3. Patheon to Present at Informex USA
4. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
5. Patheon to Present at 2013 DCAT Week
6. Patheon to Present New Updates in Drug Formulation and Bioavailability
7. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
10. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
11. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides users ... said Mark Tess, PhD, Mycotoxin Product Manager for Charm Sciences. ... USDA-GIPSA inspection agencies that have a need to detect aflatoxin ... a matter of minutes with nothing but our equipment and ... grain before accepting it, but they no longer have to ...
(Date:8/28/2014)... Grove, PA (PRWEB) August 28, 2014 ... and create a culture that will allow individuals to ... are becoming increasingly important for employers looking to compete ... science industries are embracing this trend, as the sector ... fabric of a company, which will have real results ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... sponges, IUDs, diaphragms-- women have many options for planning their ... men want to help out? They have only two options ... crucial for dating but get old in long-term relationships. ... that nobody is every calling them "Daddy" before they are ...
... PPD, Inc. (Nasdaq:,PPDI) will release its third quarter 2007 ... The earnings release will be available,on the PPD Web ... On Wednesday, October 24, at 9 a.m. ET, ... to discuss financial results and the,overall business environment. A ...
... 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... interim results from a U.K. Phase Ia/Ib ... with advanced or,metastatic cancers is scheduled to ... (NCRI) conference on October 2, 2007 in ...
Cached Biology Technology:Of mice and men: new male contraceptives successful in rodents and humans 2PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 4
(Date:8/28/2014)... for delivering compounds that could positively impact ... may be possible, thanks to researchers in ... semi-soft vaginal suppository made from the seaweed-derived ... antiviral drug Tenofovir provides a woman-initiated, drug-delivery ... of sexually transmitted infections during unprotected heterosexual ...
(Date:8/28/2014)... August 28, 2014 Dyslexia, the most commonly ... a neurological reading disability that occurs when the ... don,t function normally. , The use of non-invasive ... activity is disrupted in dyslexia. However, most prior ... of brain regions, leaving a gap in our ...
(Date:8/28/2014)... the first person to alert the world to Global ... be captured and stored underground. He says that Carbon ... the best way to avoid global warming getting out ... (Columbia University, New York) made the call during his ... where 150 scientists are meeting to discuss Carbon Capture ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Dyslexic readers have disrupted network connections in the brain 2Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2
... and molecular biologists, chemists, physicists, material scientists, computational modelers ... the newly funded Center for Lignocellulose Structure and Formation, ... Penn State. The DOE plans to fund the ... Cosgrove, professor of biology, will direct the Center in ...
... human brain stores some kinds of memories for a ... at things, our gray matter also creates temporary memories ... seconds these visual memories exist. For decades, scientists have ... grow gradually more imprecise over the course of several ...
... A new longitudinal study of children,s personality traits ... differently in girls and boys. The study, by ... of Hawaii at Manoa, and Purdue University, appears ... Child Development . The researchers looked ...
Cached Biology News:Center to investigate plant cells for better biomass fuels 2Some short-term memories die suddenly, no fading 2Sugar, spice and puppy dog tails: Developing sex-typed personality traits and interests 2
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
Simple operation and an easy-to-read LCD display characterize our Classic Light balances. * Taring range 0...1510 g...
... SLi 3 •3H 2 O Formula Weight: 881.42 ... pH 7.0): greater than or equal to 90% lambda max : 259 ... Spectral Ratios: A 232 /A 260 : 0.51 ... 280 /A 260 : 0.17 0.02 Storage: -20C ...
Biology Products: